You have free access to this content

Cancer

Cover image for Cancer

1 May 2007

Volume 109, Issue 9

Pages 1697–1928

  1. A Note From History

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
      Soft tissue sarcomas (pages 1697–1704)

      Steven I. Hajdu

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22608

      Sarcomas have been diagnosed from ancient times, but the term sarcoma was used for benign as well as malignant tumors until the middle 1800s. The treatment for soft tissue sarcomas was surgery for 2000 years. In the 1970s, multimodality therapy and the TNM system for staging were introduced.

  2. Review Articles

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
      The incidence and impact of thrombocytopenia in myelodysplastic syndromes (pages 1705–1714)

      Hagop Kantarjian, Francis Giles, Alan List, Roger Lyons, Mikkael A. Sekeres, Sherry Pierce, Robert Deuson and Joseph Leveque

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22602

      Thrombocytopenia is common in myelodysplastic syndromes (MDS) with an increased prevalence in higher-risk International Prognostic Scoring System categories, and many approved and investigational MDS therapies cause or exacerbate preexisting thrombocytopenia. The incidence of severe bleeding in MDS was higher than reported in current guidelines.

  3. Original Articles

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. Disease Site

      Breast Disease
      You have free access to this content
      Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction (pages 1715–1720)

      Amy K. Alderman, Sarah T. Hawley, Jennifer Waljee, Monica Morrow and Steven J. Katz

      Article first published online: 26 MAR 2007 | DOI: 10.1002/cncr.22598

      The results of this study indicated that there are systematic differences among general surgeons regarding referral to plastic surgeons prior to mastectomy for patients with breast cancer. Women need more opportunities to discuss reconstructive options so that they may make informed surgical treatment decisions about their breast cancer.

    2. You have free access to this content
      Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : A population-based study from the California cancer Registry (pages 1721–1728)

      Katrina R. Bauer, Monica Brown, Rosemary D. Cress, Carol A. Parise and Vincent Caggiano

      Article first published online: 26 MAR 2007 | DOI: 10.1002/cncr.22618

      The authors used data from the California Cancer Registry to investigate the patient and tumor characteristics associated with triple-negative breast cancers (estrogen receptor-, progesterone receptor-, and HER2-negative). Compared with other breast cancers, women with triple-negative breast cancer are more likely to be younger, non-Hispanic black, diagnosed at a later stage, diagnosed with a more aggressive grade, and to have poorer survival.

    3. You have free access to this content
      Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival (pages 1729–1735)

      Chuanzhong Ye, Qiuyin Cai, Qi Dai, Xiao-ou Shu, Aesun Shin, Yu-Tang Gao and Wei Zheng

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22592

      The expression levels of the ATM gene were evaluated in breast tissues from patients diagnosed with breast cancer or benign breast disease and the prognostic value of ATM gene expression patterns was investigated in breast cancer patients.

    4. Endocrine Disease
      You have free access to this content
      Trends in the incidence and treatment of parathyroid cancer in the United States (pages 1736–1741)

      Peter K. Lee, Stephanie L. Jarosek, Beth A. Virnig, Maria Evasovich and Todd M. Tuttle

      Article first published online: 19 MAR 2007 | DOI: 10.1002/cncr.22599

      The incidence of parathyroid cancer was very low, but it significantly increased in the United States from 1988 to 2003. The rate of surgical treatment also increased.

    5. Gastrointestinal Disease
      You have free access to this content
      Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma (pages 1742–1749)

      Birgitta Clinchy, Annelie Fransson, Bengt Druvefors, Anna Hellsten, Annika Håkansson, Bertil Gustafsson, Rune Sjödahl and Leif Håkansson

      Article first published online: 7 MAR 2007 | DOI: 10.1002/cncr.22623

      Preoperative analysis of lipopolysaccharide-induced interleukin-6 production by peripheral blood mononuclear cells in vitro can predict survival after radical surgery for colorectal cancer. Preoperative prognostic information could provide an important guide both for pre- and postoperative oncologic treatment and the surgical procedure.

    6. You have free access to this content
      Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer (pages 1750–1755)

      Prajnan Das, John M. Skibber, Miguel A. Rodriguez-Bigas, Barry W. Feig, George J. Chang, Robert A. Wolff, Cathy Eng, Sunil Krishnan, Nora A. Janjan and Christopher H. Crane

      Article first published online: 26 MAR 2007 | DOI: 10.1002/cncr.22625

      The objective of this study was to identify predictors of pathologic response in 562 patients who received preoperative chemoradiation for rectal cancer. The circumferential extent of tumor independently predicted the pathologic complete response rate, whereas the circumferential extent of tumor and the distance from the anal verge independently predicted the tumor downstaging rate.

    7. Genitourinary Disease
      You have free access to this content
      Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI) (pages 1756–1762)

      Scott M. Gilbert, David P. Wood, Rodney L. Dunn, Alon Z. Weizer, Cheryl T. Lee, James E. Montie and John T. Wei

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22556

      Limitations in bladder cancer health-related quality of life (HRQOL) measures have prevented a comprehensive assessment of the impact of therapy in bladder cancer patients managed with different treatment modalities. Using the recently developed Bladder Cancer Index (BCI) we sought to address this limitation. Differences in mean HRQOL scores were apparent in urinary, bowel, and sexual domains across treatment types, indicating the BCI is responsive to HRQOL differences in a wide range of bladder cancer patients.

    8. You have free access to this content
      Five-year survival after surgical treatment for kidney cancer : A population-based competing risk analysis (pages 1763–1768)

      John M. Hollingsworth, David C. Miller, Stephanie Daignault and Brent K. Hollenbeck

      Article first published online: 9 MAR 2007 | DOI: 10.1002/cncr.22600

      It is demonstrated that nearly one-third of elderly patients (ie, patients aged 70 years and older) will die from competing causes within 5 years of curative surgery for their kidney cancers. As such, the data suggest the need for prospective studies to evaluate the role of active surveillance as an initial therapeutic approach for some small renal masses.

    9. You have free access to this content
      Education predicts quality of life among men with prostate cancer cared for in the department of Veterans affairs : A longitudinal quality of life analysis from CaPSURE (pages 1769–1776)

      Sara J. Knight, David M. Latini, Stacey L. Hart, Natalia Sadetsky, Christopher J. Kane, Janeen DuChane, Peter R. Carroll and the CaPSURE Investigators

      Article first published online: 22 MAR 2007 | DOI: 10.1002/cncr.22597

      Men with less education experience worse health-related quality of life across a wide range of domains than their peers who have more education. Clinicians should be aware that men with less education are vulnerable, having greater difficulty functioning in their daily lives after their prostate cancer treatment.

    10. You have free access to this content
      Assessment of prognosis with the total illness burden index for prostate cancer : Aiding clinicians in treatment choice (pages 1777–1783)

      Mark S. Litwin, Sheldon Greenfield, Eric P. Elkin, Deborah P. Lubeck, Jeanette M. Broering and Sherrie H. Kaplan

      Article first published online: 12 MAR 2007 | DOI: 10.1002/cncr.22615

      Men who had the highest scores on the Total Illness Burden Index for Prostate Cancer (TIBI-CaP), a patient-reported measure of comorbidity, were 13 times more likely to die of causes other than prostate cancer over the subsequent 3.5 years after initial treatment than men who had the lowest scores. Because the TIBI-CaP identified patients at high risk for nonprostate cancer mortality, it may aid physicians and patients in making appropriate treatment decisions.

    11. Gynecologic Oncology
      You have free access to this content
      Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation (pages 1784–1790)

      Fatima Laki, Youlia M. Kirova, Pascale This, for the IC-BOCRSG , Corinne Plancher, Bernard Asselain, Xavier Sastre, Dominique Stoppa-Lyonnet and Remy Salmon

      Article first published online: 9 MAR 2007 | DOI: 10.1002/cncr.22603

      A series of 89 BRCA1/BRCA2 mutation carriers who underwent prophylactic salpingo-oophorectomy was analyzed. Occult ovarian/fallopian carcinoma was found in 4 patients (4.5%), but no peritoneal malignancy was observed with a mean follow-up of 40 months.

    12. Head and Neck Disease
      You have free access to this content
      P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases : New results for an old question (pages 1791–1798)

      Rubén Cabanillas, Juan Pablo Rodrigo, Aurora Astudillo, Francisco Domínguez, Carlos Suárez and Maria Dolores Chiara

      Article first published online: 22 MAR 2007 | DOI: 10.1002/cncr.22646

      The objective of this study was to investigate the expression pattern and prognostic significance of p53 expression in head and neck squamous cell carcinomas (SCCs) of the same location, treated in the same way, and with long-term follow-up. The results indicated that p53 overexpression in the lymph node metastases from SCCs of the supraglottic larynx was an independent predictor of regional failure and a poor prognosis.

    13. Hematologic Malignancies
      You have free access to this content
      Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma (pages 1799–1803)

      David J. Straus, Madeleine Duvic, Timothy Kuzel, Steven Horwitz, Marie-France Demierre, Patricia Myskowski and Steven Steckel

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22596

      The efficacy and safety of oral bexarotene alone and then with the addition of subcutaneous interferon alfa-2b was evaluated in patients with cutaneous T-cell lymphoma. The combination was safe. The response rate was similar to that reported with bexarotene alone.

    14. You have free access to this content
      Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan (pages 1804–1810)

      Thomas E. Witzig, Arturo Molina, Leo I. Gordon, Christos Emmanouilides, Russell J. Schilder, Ian W. Flinn, Mohamed Darif, Roger Macklis, Katie Vo and Gregory A. Wiseman

      Article first published online: 22 MAR 2007 | DOI: 10.1002/cncr.22617

      Collective data from 4 clinical trials demonstrate that yttrium 90 ibritumomab tiuxetan produced long-term remissions in 37% (78 of 211) of patients with recurring or refractory non-Hodgkin lymphoma. The estimated 5-year overall survival of 53% for all patients treated with yttrium 90 ibritumomab tiuxetan and 81% for patients with long-term responses is encouraging for this population in whom previous therapies had failed.

    15. Heptobiliary Disease
      You have free access to this content
      Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin (pages 1811–1820)

      Sarah K. Johnson, Vishnu C. Ramani, Leah Hennings and Randy S. Haun

      Article first published online: 12 MAR 2007 | DOI: 10.1002/cncr.22606

      Kallikrein 7 is overexpressed in pancreatic tumors. Shedding of E-cadherin by human kallikrein 7 (hK7) proteolytic activity increases pancreatic cell invasiveness and decreases cell aggregation.

    16. Lung Disease
      You have free access to this content
      Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy (pages 1821–1828)

      Yuh-Min Chen, Jacqueline Ming Liu, Teh-Ying Chou, Reury-Perng Perng, Chun-Ming Tsai and Jacqueline Whang-Peng

      Article first published online: 9 MAR 2007 | DOI: 10.1002/cncr.22616

      Gefitinib was highly effective in ethnic Chinese patients with adenocarcinoma of the lung who failed previous platinum and taxane treatment. The addition of low-dose vinorelbine every 2 weeks produced a significantly better 1-year progression-free survival rate.

    17. You have free access to this content
      Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer (pages 1829–1835)

      Yong Wha Moon, Sung Ho Choi, Yong Tai Kim, Joo Hyuk Sohn, Joon Chang, Se Kyu Kim, Moo Suk Park, Kyung Young Chung, Hyoun Ju Lee and Joo-Hang Kim

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22601

      The study investigated correlations between adenosine triphosphate/chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-guided platinum-based chemotherapy for unresectable nonsmall-cell lung cancer.

    18. You have free access to this content
      Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer (pages 1836–1844)

      Takashi Sone, Kazuo Kasahara, Hideharu Kimura, Kazuto Nishio, Masayuki Mizuguchi, Yasuto Nakatsumi, Kazuhiko Shibata, Yuko Waseda, Masaki Fujimura and Shinji Nakao

      Article first published online: 26 MAR 2007 | DOI: 10.1002/cncr.22593

      The results from this study indicated that epidermal growth factor receptor (EGFR) mutations may serve as predictors of response and survival and that the role of EGFR gene amplification is not a predictor of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.

    19. Discipline

      Pathology
      You have free access to this content
      Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer (pages 1845–1950)

      Joo Hyuk Sohn, Yong Wha Moon, Chang Geol Lee, Gwi Eon Kim, Kyung Young Chung, Joon Chang, Se Kyu Kim, Young Sam Kim, Byoung Wook Choi, Hye Jin Choi and Joo-Hang Kim

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22621

      Irinotecan and cisplatin with early concurrent radiotherapy was first tested in limited-disease small-cell lung cancer (LD-SCLC) and the protocol was effective and tolerable in untreated LD-SCLC.

    20. Disease Site

      Neuro-Oncology
      You have free access to this content
      Acute binocular blindness (pages 1851–1854)

      Marc C. Chamberlain and Lisa Chalmers

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22619

      Ten patients with acute onset blindness were seen, of whom 6 made a complete or near complete recovery. Treatment varied and was determined by etiology of visual loss.

    21. You have free access to this content
      Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS) (pages 1855–1862)

      Wolfram E. Samlowski, Gordon A. Watson, Michael Wang, Ganesh Rao, Paul Klimo Jr, Kenneth Boucher, Dennis C. Shrieve and Randy L. Jensen

      Article first published online: 9 MAR 2007 | DOI: 10.1002/cncr.22605

      Brain metastases are a frequent and adverse complication in advanced melanoma. Aggressive treatment of patients with melanoma brain metastases incorporating stereotactic radiosurgery and subsequent systemic therapy appears to result in prolonged survival.

    22. Sarcoma
      You have free access to this content
      Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas : Results of a phase II trial (pages 1863–1869)

      Palma Dileo, Jeffrey A. Morgan, David Zahrieh, Jayesh Desai, Jeanine M. Salesi, David C. Harmon, M. Travis Quigley, Kathleen Polson, George D. Demetri and Suzanne George

      Article first published online: 23 MAR 2007 | DOI: 10.1002/cncr.22609

      Gemcitabine given by a fixed-dose rate of infusion combined with vinorelbine is associated with clinically meaningful rates of disease control with acceptable toxicity in patients with advanced soft-tissue sarcoma.

    23. You have free access to this content
      COPS3 amplification and clinical outcome in osteosarcoma (pages 1870–1876)

      Taiqiang Yan, Jay S. Wunder, Nalan Gokgoz, Mona Gill, Sasha Eskandarian, Robert K. Parkes, Shelley B. Bull, Robert S. Bell and Irene L. Andrulis

      Article first published online: 15 MAR 2007 | DOI: 10.1002/cncr.22595

      The study shows that 31% of high-grade osteosarcomas harbor COPS3 gene amplification and this is strongly associated with large tumor size. COPS3 gene amplification is significantly correlated with a shorter time to metastasis in univariate analysis, but not in multivariate analysis, mainly due to the strong correlation with tumor size.

    24. Discipline

      Cancer Disparities
      You have free access to this content
      Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey (pages 1877–1886)

      Angela B. Mariotto, Ruth Etzioni, Martin Krapcho and Eric J. Feuer

      Article first published online: 19 MAR 2007 | DOI: 10.1002/cncr.22607

      To reconstruct patterns of prostate-specific antigen (PSA) testing in the US and to determine the extent of any racial disparity in PSA use, the 2000 National Health Interview Survey and longitudinal Medicare claims data were combined to estimate rates of initial and subsequent tests. Results from a simulation model that reconstructs individual screening histories showed that, overall, 45% of white men and 43% of black men between ages 40–84 years had at least 1 PSA test by the year 2000. Fairly similar patterns in overall PSA testing between blacks and whites indicate that racial disparity in PSA testing is probably not a major factor behind current racial differences in prostate cancer mortality rates and declines.

    25. Epidemiology
      You have free access to this content
      Ovarian cancer screening with annual transvaginal sonography : Findings of 25,000 women screened (pages 1887–1896)

      John R. van Nagell Jr, Paul D. DePriest, Frederick R. Ueland, Christopher P. DeSimone, Amy L. Cooper, J. Matt McDonald, Edward J. Pavlik and Richard J. Kryscio

      Article first published online: 20 MAR 2007 | DOI: 10.1002/cncr.22594

      The authors investigated the efficacy of annual transvaginal sonography (TVS) as a screening method for ovarian cancer. TVS screening, when performed annually, was associated with a decrease in disease stage at the time of initial detection and with case-specific ovarian cancer mortality, but it was not effective for detecting ovarian cancers in which the ovarian volume was normal.

    26. Medical Oncology
      You have free access to this content
      Imatinib mesylate for targeting the platelet-derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer—A dose-escalation Phase I trial (pages 1897–1904)

      Salah-Eddin Al-Batran, Akin Atmaca, Eberhard Schleyer, Claudia Pauligk, Christian Hosius, Gerhard Ehninger and Elke Jäger

      Article first published online: 20 MAR 2007 | DOI: 10.1002/cncr.22622

      The combination of biweekly fluorouracil/leucovorin and imatinib 600 mg daily given in a week-on/week-off schedule for patients with gastrointestinal tumors was feasible and safe. Nausea and fluid retention represented the dose-limiting toxicities.

    27. Discipline

      Psychological Oncology
      You have free access to this content
      Cognitive function during neoadjuvant chemotherapy for breast cancer : Results of a prospective, multicenter, longitudinal study (pages 1905–1913)

      Kerstin Hermelink, Michael Untch, Michael P. Lux, Rolf Kreienberg, Thomas Beck, Ingo Bauerfeind and Karin Münzel

      Article first published online: 9 MAR 2007 | DOI: 10.1002/cncr.22610

      Cognitive compromise already is present in breast cancer patients even before the start of any therapy. In this study, during chemotherapy, cognitive performance declined in a subgroup of patients, improved in a commensurate subgroup, and remained stable in the majority of patients.

    28. Symptom Control and Palliative Care
      You have free access to this content
      Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire (pages 1914–1922)

      Joel B. Epstein, Jennifer L. Beaumont, Clement K. Gwede, Barbara Murphy, Adam S. Garden, Ruby Meredith, Quynh-Thu Le, David Brizel, John Isitt and David Cella

      Article first published online: 20 MAR 2007 | DOI: 10.1002/cncr.22620

      The Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN) is a valid, reliable, and feasible instrument for assessing the impact of mucositis on patients with head and neck cancer who are receiving radiation therapy with or without chemotherapy. The OMWQ-HN demonstrated good test-retest reliability, validity across differing levels of pain, and strong correlations with the Functional Assessment of Cancer Therapy-Head and Neck.

  4. Correspondence

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
  5. Response to Letter to the Editors

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
      Author reply (page 1924)

      Edward M. Messing and Ralph Madeb

      Article first published online: 14 MAR 2007 | DOI: 10.1002/cncr.22591

  6. Correspondence

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
  7. Letter to the Editors

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
      Author reply (page 1926)

      Graeme P. Young

      Article first published online: 16 MAR 2007 | DOI: 10.1002/cncr.22612

  8. Correspondence

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
  9. Response to Letter to the Editors

    1. Top of page
    2. A Note From History
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Response to Letter to the Editors
    7. Correspondence
    8. Letter to the Editors
    9. Correspondence
    10. Response to Letter to the Editors
    1. You have free access to this content
      Author reply (page 1928)

      Gary M. Freedman

      Article first published online: 12 MAR 2007 | DOI: 10.1002/cncr.22614

SEARCH

SEARCH BY CITATION